Picton Mahoney Asset Management grew its stake in Penumbra Inc (NYSE:PEN) by 0.5% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 13,140 shares of the company’s stock after purchasing an additional 70 shares during the quarter. Picton Mahoney Asset Management’s holdings in Penumbra were worth $2,102,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors also recently modified their holdings of the business. FMR LLC increased its stake in shares of Penumbra by 3.4% in the 1st quarter. FMR LLC now owns 5,197,972 shares of the company’s stock worth $764,155,000 after acquiring an additional 173,056 shares in the last quarter. Thoroughbred Financial Services LLC increased its stake in shares of Penumbra by 16,171.3% in the 2nd quarter. Thoroughbred Financial Services LLC now owns 1,247,360 shares of the company’s stock worth $124,736,000 after acquiring an additional 1,239,694 shares in the last quarter. Baillie Gifford & Co. increased its stake in shares of Penumbra by 2.1% in the 1st quarter. Baillie Gifford & Co. now owns 924,904 shares of the company’s stock worth $135,969,000 after acquiring an additional 18,882 shares in the last quarter. Clearbridge Investments LLC increased its stake in shares of Penumbra by 10.1% in the 1st quarter. Clearbridge Investments LLC now owns 813,016 shares of the company’s stock worth $119,521,000 after acquiring an additional 74,377 shares in the last quarter. Finally, Redmile Group LLC increased its stake in shares of Penumbra by 121.9% in the 1st quarter. Redmile Group LLC now owns 323,170 shares of the company’s stock worth $47,509,000 after acquiring an additional 177,562 shares in the last quarter. Institutional investors and hedge funds own 92.11% of the company’s stock.
NYSE:PEN traded down $5.18 on Friday, reaching $139.74. 256,923 shares of the stock traded hands, compared to its average volume of 492,648. The company has a market capitalization of $5.04 billion, a price-to-earnings ratio of 274.00, a PEG ratio of 8.30 and a beta of 0.65. The company has a current ratio of 6.23, a quick ratio of 4.33 and a debt-to-equity ratio of 0.10. Penumbra Inc has a 12 month low of $110.84 and a 12 month high of $185.70. The company’s fifty day simple moving average is $162.93 and its 200 day simple moving average is $150.55.
Several research analysts recently issued reports on PEN shares. Bank of America increased their price target on shares of Penumbra from $150.00 to $180.00 and gave the stock a “buy” rating in a research note on Thursday, June 13th. Wells Fargo & Co increased their price target on shares of Penumbra from $180.00 to $185.00 and gave the stock an “outperform” rating in a research note on Thursday, August 1st. Zacks Investment Research lowered shares of Penumbra from a “buy” rating to a “hold” rating in a research note on Thursday, August 1st. William Blair began coverage on shares of Penumbra in a research note on Tuesday, May 21st. They set an “outperform” rating for the company. Finally, ValuEngine lowered shares of Penumbra from a “buy” rating to a “hold” rating in a research note on Thursday, August 1st. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Penumbra presently has a consensus rating of “Buy” and a consensus price target of $167.14.
In other Penumbra news, EVP Lynn Rothman sold 5,000 shares of the firm’s stock in a transaction dated Monday, August 19th. The shares were sold at an average price of $144.66, for a total transaction of $723,300.00. Following the completion of the sale, the executive vice president now directly owns 12,012 shares in the company, valued at approximately $1,737,655.92. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Adam Elsesser sold 8,000 shares of the firm’s stock in a transaction dated Tuesday, June 11th. The shares were sold at an average price of $165.08, for a total transaction of $1,320,640.00. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 44,412 shares of company stock valued at $7,042,018. 9.60% of the stock is owned by company insiders.
Penumbra Company Profile
Penumbra, Inc designs, develops, manufactures, and markets medical devices in the United States, Europe, Canada, Australia, Japan, and internationally. The company offers neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, DDC, and PX SLIM brands; aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the ACE and the 3D Revascularization Device brands.
Further Reading: Average Daily Trade Volume – ADTV
Want to see what other hedge funds are holding PEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Penumbra Inc (NYSE:PEN).
Receive News & Ratings for Penumbra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Penumbra and related companies with MarketBeat.com's FREE daily email newsletter.